BR112014000333A2 - método de tratamento de aterosclerose em sujeitos com triglicerídeo alto - Google Patents
método de tratamento de aterosclerose em sujeitos com triglicerídeo altoInfo
- Publication number
- BR112014000333A2 BR112014000333A2 BR112014000333A BR112014000333A BR112014000333A2 BR 112014000333 A2 BR112014000333 A2 BR 112014000333A2 BR 112014000333 A BR112014000333 A BR 112014000333A BR 112014000333 A BR112014000333 A BR 112014000333A BR 112014000333 A2 BR112014000333 A2 BR 112014000333A2
- Authority
- BR
- Brazil
- Prior art keywords
- high triglyceride
- subjects
- atherosclerosis
- treatment method
- atherosclerosis treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
Abstract
resumo patente de invenção: "método de tratamento de aterosclerose em sujeitos com triglicerídeo alto". a presente invenção refere-se a um composto de fórmula i: i para uso no tratamento, melhora e/ou prevenção de doenças e condições associadas com atividade de cetp, tal como aterosclerose e dislipidemia, em um sujeito com nível de triglicerídeo alto; em que r1, x1, r7, r5, c, l e p são definidos aqui. a presente invenção também fornece uma combinação de agentes farmacologicamente ativos para uso no tratamento, melhora e/ou prevenção de doenças e condições associadas com atividade de cetp, tal como aterosclerose e dislipidemia, em um sujeito com níveis de triglicerídeo altos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161505584P | 2011-07-08 | 2011-07-08 | |
US201261657061P | 2012-06-08 | 2012-06-08 | |
PCT/IB2012/053479 WO2013008164A2 (en) | 2011-07-08 | 2012-07-06 | Method of treating atherosclerosis in high triglyceride subjects |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014000333A2 true BR112014000333A2 (pt) | 2017-02-07 |
Family
ID=46724554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014000333A BR112014000333A2 (pt) | 2011-07-08 | 2012-07-06 | método de tratamento de aterosclerose em sujeitos com triglicerídeo alto |
Country Status (17)
Country | Link |
---|---|
US (2) | US9867811B2 (pt) |
EP (1) | EP2729142B1 (pt) |
JP (2) | JP2014520795A (pt) |
KR (2) | KR20140056258A (pt) |
CN (2) | CN103648495A (pt) |
AU (1) | AU2012282109B2 (pt) |
BR (1) | BR112014000333A2 (pt) |
CA (1) | CA2841117A1 (pt) |
ES (1) | ES2683350T3 (pt) |
MX (1) | MX2014000342A (pt) |
PL (1) | PL2729142T3 (pt) |
PT (1) | PT2729142T (pt) |
RU (1) | RU2609200C2 (pt) |
SG (1) | SG10201605304VA (pt) |
TW (1) | TWI627167B (pt) |
WO (1) | WO2013008164A2 (pt) |
ZA (1) | ZA201400176B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201335109A (zh) * | 2011-12-02 | 2013-09-01 | Kowa Co | 光學活性化合物之製造方法 |
WO2014017569A1 (ja) * | 2012-07-26 | 2014-01-30 | 興和株式会社 | 血中ldlを低下させるための医薬 |
WO2014128564A2 (en) * | 2013-02-21 | 2014-08-28 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of cetp inhibitors |
JP2017528471A (ja) | 2014-09-24 | 2017-09-28 | ギリアード サイエンシーズ, インコーポレイテッド | 肝疾患を処置する方法 |
TWI691331B (zh) * | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
US20170252338A1 (en) * | 2014-11-28 | 2017-09-07 | Kowa Company, Ltd. | Medicine |
JPWO2016084950A1 (ja) * | 2014-11-28 | 2017-09-07 | 興和株式会社 | 医薬組成物 |
WO2018020477A1 (en) * | 2016-07-28 | 2018-02-01 | The Regents Of The University Of California | Methods and compositions for treating hypertriglyceridemia |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
MXPA02010091A (es) | 2000-04-12 | 2003-02-12 | Novartis Ag | Novedoso uso medico de inhibidores de sintasa de aldosterona solos o en combinacion con antagonistas del receptor at-1. |
BR0209238A (pt) * | 2001-04-30 | 2004-06-15 | Pfizer Prod Inc | Compostos úteis como intermediários |
ES2270143T3 (es) | 2002-08-07 | 2007-04-01 | Novartis Ag | Compuestos organicos como agentes para el tratamiento de condiciones mediadas por aldosterona. |
DK1533292T3 (da) * | 2002-08-30 | 2007-06-04 | Japan Tobacco Inc | Dibenzylaminforbindelse og medicinsk anvendelse deraf |
ATE398124T1 (de) | 2002-11-18 | 2008-07-15 | Novartis Pharma Gmbh | Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron |
JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
PL1732933T3 (pl) | 2004-03-26 | 2008-12-31 | Lilly Co Eli | Związki do leczenia dyslipidemii |
DE602005025110D1 (de) | 2004-05-28 | 2011-01-13 | Novartis Ag | Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren |
EP2261225A1 (en) | 2004-05-28 | 2010-12-15 | Novartis AG | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
CA2568159A1 (en) | 2004-05-28 | 2005-12-15 | Speedel Experimenta Ag | Tetrahydro-imidazo [1,5-a] pyridin derivatives as aldosterone synthase inhibitors |
WO2006012093A1 (en) | 2004-06-24 | 2006-02-02 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
TW200611897A (en) | 2004-07-09 | 2006-04-16 | Speedel Experimenta Ag | Organic compounds |
US20060063803A1 (en) | 2004-09-23 | 2006-03-23 | Pfizer Inc | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds |
JP2008520645A (ja) * | 2004-11-23 | 2008-06-19 | ファイザー・プロダクツ・インク | ジベンジルアミン化合物および誘導体 |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716105A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
AR056888A1 (es) | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
KR20080086917A (ko) * | 2005-12-29 | 2008-09-26 | 노파르티스 아게 | 콜레스테릴 에스테르 전달 단백질 (cetp) 억제제로서의피리디닐 아민 유도체 |
KR20140107671A (ko) | 2005-12-30 | 2014-09-04 | 머크 샤프 앤드 돔 코포레이션 | Cetp 억제제로서 유용한 1,3-옥사졸리딘-2-온 유도체 |
JP5199121B2 (ja) * | 2005-12-30 | 2013-05-15 | メルク・シャープ・エンド・ドーム・コーポレイション | Cetp阻害剤 |
US7910592B2 (en) | 2005-12-30 | 2011-03-22 | Merck Sharp & Dohme Corp. | CETP inhibitors |
UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
US8030359B2 (en) | 2006-02-09 | 2011-10-04 | Merck Sharp & Dohme Corp. | Polymer formulations of CETP inhibitors |
US8383660B2 (en) | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
SI2402317T1 (sl) | 2006-03-31 | 2013-10-30 | Novartis Ag | DGAT inhibitor |
CN101415803B (zh) | 2006-04-04 | 2012-10-24 | 大阳日酸株式会社 | 甲烷分离方法、甲烷分离装置以及甲烷利用*** |
TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
TW200808812A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
AU2007247385B2 (en) | 2006-05-10 | 2011-07-14 | Novartis Ag | Bicyclic derivatives as CETP inhibitors |
AU2007259143A1 (en) | 2006-06-08 | 2007-12-21 | Amgen Inc. | Benzamide derivatives and uses related thereto |
EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
JP5042311B2 (ja) | 2006-07-20 | 2012-10-03 | ノバルティス アーゲー | Cetp阻害剤としてのアミノピペリジン誘導体 |
DE102006034048B4 (de) * | 2006-07-20 | 2016-05-19 | Wanzl Metallwarenfabrik Gmbh | Einkaufswagen |
JP2010501573A (ja) | 2006-08-25 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | アルドステロン合成酵素および/または11−β−ヒドロキシラーゼおよび/またはアロマターゼが介在する疾患の処置のための縮合イミダゾール誘導体 |
KR20090094374A (ko) | 2006-12-18 | 2009-09-04 | 노파르티스 아게 | 1-치환된 이미다졸 유도체 및 알도스테론 신타제 억제제로서의 그의 용도 |
MX2009006630A (es) | 2006-12-18 | 2009-06-30 | Novartis Ag | Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa. |
EA200900811A1 (ru) | 2006-12-18 | 2009-12-30 | Новартис Аг | Имидазолы в качестве ингибиторов альдостеронсинтазы |
EP2120928A2 (en) | 2007-02-15 | 2009-11-25 | Pfizer Limited | Pharmaceutical compositions and methods for ccr5 antagonists |
WO2008119744A1 (en) | 2007-03-29 | 2008-10-09 | Novartis Ag | Heterocyclic spiro-compounds |
EP2149563B9 (en) | 2007-04-13 | 2015-04-22 | Kowa Company, Ltd. | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound |
JP4834699B2 (ja) | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
JP4846769B2 (ja) | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | 医薬組成物 |
WO2009027785A2 (en) | 2007-08-30 | 2009-03-05 | Pfizer Products Inc. | 1, 3-oxazole derivatives as cetp inhibitors |
AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
PE20090982A1 (es) * | 2007-11-05 | 2009-08-13 | Novartis Ag | Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) |
EP2229356B1 (en) * | 2007-12-03 | 2011-10-12 | Novartis AG | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis |
AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
MA33358B1 (fr) | 2009-05-15 | 2012-06-01 | Novartis Ag | Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase |
AR077208A1 (es) | 2009-06-30 | 2011-08-10 | Lilly Co Eli | Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam |
WO2011028395A1 (en) | 2009-08-24 | 2011-03-10 | Merck Sharp & Dohme Corp. | Pyridyl oxazolidinone cetp inhibitor |
-
2012
- 2012-07-06 RU RU2014104377A patent/RU2609200C2/ru not_active IP Right Cessation
- 2012-07-06 PL PL12750616T patent/PL2729142T3/pl unknown
- 2012-07-06 WO PCT/IB2012/053479 patent/WO2013008164A2/en active Application Filing
- 2012-07-06 KR KR1020147002988A patent/KR20140056258A/ko active Application Filing
- 2012-07-06 MX MX2014000342A patent/MX2014000342A/es unknown
- 2012-07-06 SG SG10201605304VA patent/SG10201605304VA/en unknown
- 2012-07-06 AU AU2012282109A patent/AU2012282109B2/en not_active Ceased
- 2012-07-06 EP EP12750616.0A patent/EP2729142B1/en not_active Not-in-force
- 2012-07-06 US US14/128,877 patent/US9867811B2/en not_active Expired - Fee Related
- 2012-07-06 TW TW101124537A patent/TWI627167B/zh not_active IP Right Cessation
- 2012-07-06 CN CN201280034037.5A patent/CN103648495A/zh active Pending
- 2012-07-06 ES ES12750616.0T patent/ES2683350T3/es active Active
- 2012-07-06 JP JP2014518058A patent/JP2014520795A/ja active Pending
- 2012-07-06 CN CN201710928984.3A patent/CN107550914A/zh active Pending
- 2012-07-06 KR KR1020197005512A patent/KR20190025737A/ko not_active Application Discontinuation
- 2012-07-06 CA CA2841117A patent/CA2841117A1/en not_active Abandoned
- 2012-07-06 PT PT12750616T patent/PT2729142T/pt unknown
- 2012-07-06 BR BR112014000333A patent/BR112014000333A2/pt not_active Application Discontinuation
-
2014
- 2014-01-09 ZA ZA2014/00176A patent/ZA201400176B/en unknown
-
2017
- 2017-01-12 JP JP2017003519A patent/JP6310581B2/ja not_active Expired - Fee Related
- 2017-12-05 US US15/831,545 patent/US20180153861A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20140056258A (ko) | 2014-05-09 |
NZ619573A (en) | 2016-04-29 |
KR20190025737A (ko) | 2019-03-11 |
JP6310581B2 (ja) | 2018-04-11 |
TWI627167B (zh) | 2018-06-21 |
PT2729142T (pt) | 2018-10-01 |
CN107550914A (zh) | 2018-01-09 |
US9867811B2 (en) | 2018-01-16 |
CN103648495A (zh) | 2014-03-19 |
PL2729142T3 (pl) | 2018-10-31 |
US20180153861A1 (en) | 2018-06-07 |
TW201311668A (zh) | 2013-03-16 |
CA2841117A1 (en) | 2013-01-17 |
ZA201400176B (en) | 2015-12-23 |
AU2012282109A1 (en) | 2014-02-27 |
RU2014104377A (ru) | 2015-08-20 |
RU2609200C2 (ru) | 2017-01-30 |
ES2683350T3 (es) | 2018-09-26 |
WO2013008164A2 (en) | 2013-01-17 |
MX2014000342A (es) | 2014-05-01 |
JP2014520795A (ja) | 2014-08-25 |
SG10201605304VA (en) | 2016-08-30 |
WO2013008164A3 (en) | 2013-05-10 |
JP2017081985A (ja) | 2017-05-18 |
EP2729142A2 (en) | 2014-05-14 |
EP2729142B1 (en) | 2018-05-09 |
US20140134262A1 (en) | 2014-05-15 |
AU2012282109B2 (en) | 2016-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014000333A2 (pt) | método de tratamento de aterosclerose em sujeitos com triglicerídeo alto | |
TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
NZ700928A (en) | Dna-pk inhibitors | |
MX2013008212A (es) | Derivados de 7-azaindol. | |
BR112014028017A2 (pt) | composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror | |
UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
EA201691121A1 (ru) | Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения | |
MX2013008192A (es) | Inhibidores de bace-2 para tratamiento de transtornos metabolicos. | |
GB2503852A (en) | Compounds for the treatment of neuropsychiatric disorders | |
BR112012018170B8 (pt) | agente antimicrobiano para redução, inibição ou tratamento do crescimento microbiano, infecções microbianas, doenças inflamatórias, doenças ou condições virais resultantes de ou associadas aos mesmos | |
EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
BR112013028420A2 (pt) | tratamento de mieloma múltiplo | |
EA201490614A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-kB | |
BR112014000634A2 (pt) | métodos para tratamento de incontinência associada com atividade sexual | |
MX2014000567A (es) | Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios. | |
MX2013010524A (es) | Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata. | |
MX2014003223A (es) | Composiciones y metodos para tratar el cancer usando el inhibidor de pi3kbeta y el inhibidor de la via de mapk, incluidos los inhibidores de mek y raf. | |
BR112012019920A2 (pt) | derivados de piridazina úteis como agonístas de canabinoide-2. | |
BR112015010196A2 (pt) | métodos de tratar doença do fígado | |
BR112012006070A2 (pt) | composições e métodos para tratar distúrbios convulsivos. | |
MX2014013049A (es) | Composiciones y metodos para sulfato de heparan como un biomarcador para rechazo de trasplante. | |
BR112014002712A8 (pt) | método para tratamento da esquizofrenia | |
CR20140289A (es) | Derivados de quinolina como inhibidores de la enzima pde10a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |